Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monopar TherapeuticsMNPR · Entity 5152 | 10% owner | December 18, 2019 | December 20, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monopar Therapeutics
Report date December 18, 2019 · Filed December 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | IndirectSee Footnote 1 | 156,250 |
Reported balance
After 2019-12-18 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-12-18 · Purchase · Acquired 156,250 · Balance 156,250 F1: This is based upon the 156,250 shares of Monopar Common Stock that KWL Investments II, LLC directly owns. As a manager of KWL Investments II, LLC, Mr. Leo may be deemed to share voting and dispositive power over these 156,250 shares. Mr. Leo disclaims beneficial ownership of the 156,250 shares held by KWL Investments II, LLC, except to the extent of his pecuniary interest therein. |
| Common stockSEC Table I · non-derivative | Direct | 313.75 |
Reported balance
After 2019-12-18 transaction · row 2
1 source rowRow 2 · 2019-12-18 · Purchase · Acquired 313.75 · Balance 313.75 |
| Common stockSEC Table I · non-derivative | IndirectSee Footnote 2 | 3,055,394.12 |
Reported balance
Holding disclosure · report date 2019-12-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,055,394.12 F2: Gem Pharmaceuticals LLC ("Gem"), an Alabama limited liability company, has voting and investment power over 3,055,394.12 of the shares of common stock held by TacticGem LLC. Karl Leo is a manager of Gem and along with other managers collectively have voting control over the securities described herein. Pharma Investments LLC ("Pharma") owns a controlling share of Gem and Karl Leo owns a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This is based upon the 156,250 shares of Monopar Common Stock that KWL Investments II, LLC directly owns. As a manager of KWL Investments II, LLC, Mr. Leo may be deemed to share voting and dispositive power over these 156,250 shares. Mr. Leo disclaims beneficial ownership of the 156,250 shares held by KWL Investments II, LLC, except to the extent of his pecuniary interest therein.
F2: Gem Pharmaceuticals LLC ("Gem"), an Alabama limited liability company, has voting and investment power over 3,055,394.12 of the shares of common stock held by TacticGem LLC. Karl Leo is a manager of Gem and along with other managers collectively have voting control over the securities described herein. Pharma Investments LLC ("Pharma") owns a controlling share of Gem and Karl Leo owns a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2019 Filed Dec 20, 2019 18:32 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon stock | 313.75 | $8.00 | $2,510.00 |
DisclosureSEC source: 0001654954-19-014149 · section16.xml · nonDerivative · entry 2 Leo Karl · CIK 0001727480 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313.75 Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 18:32 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon stock | 156,250 | $8.00 | $1,250,000.00 |
DisclosureSEC source: 0001654954-19-014149 · section16.xml · nonDerivative · entry 1 Leo Karl · CIK 0001727480 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote 1 Disclosed balance after: 156,250 F1 · ownership.nature: This is based upon the 156,250 shares of Monopar Common Stock that KWL Investments II, LLC directly owns. As a manager of KWL Investments II, LLC, Mr. Leo may be deemed to share voting and dispositive power over these 156,250 shares. Mr. Leo disclaims beneficial ownership of the 156,250 shares held by KWL Investments II, LLC, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.